Elanco Animal Health Stock Price, News & Analysis (NYSE:ELAN)

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ELAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELAN, but not buy additional shares or sell existing shares.
View ELAN analyst ratings or view top-rated stocks.

5 analysts have issued 12 month price targets for Elanco Animal Health's stock. Their ELAN share price targets range from $9.50 to $16.00. On average, they anticipate the company's share price to reach $12.70 in the next year. This suggests that the stock has a possible downside of 1.3%.
View analysts price targets for ELAN or view top-rated stocks among Wall Street analysts.

Elanco Animal Health's stock was trading at $12.22 on January 1st, 2023. Since then, ELAN stock has increased by 5.3% and is now trading at $12.87.
View the best growth stocks for 2023 here.

Elanco Animal Health saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 12,050,000 shares, an increase of 10.2% from the October 15th total of 10,930,000 shares. Based on an average daily volume of 5,170,000 shares, the days-to-cover ratio is presently 2.3 days.
View Elanco Animal Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our ELAN earnings forecast.

Elanco Animal Health Incorporated (NYSE:ELAN) issued its quarterly earnings data on Tuesday, November, 7th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.12 by $0.06. The firm earned $1.07 billion during the quarter, compared to analysts' expectations of $1.04 billion. Elanco Animal Health had a positive trailing twelve-month return on equity of 6.99% and a negative net margin of 26.18%. The company's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.20 EPS.

ETFs with the largest weight of Elanco Animal Health (NYSE:ELAN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust Health Care AlphaDEX Fund (FXH), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), Principal Healthcare Innovators ETF (BTEC), VanEck Agribusiness ETF (MOO) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Elanco Animal Health updated its FY 2023 earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $0.88-$0.94 for the period, compared to the consensus earnings per share estimate of $0.85. The company issued revenue guidance of $4.36 billion-$4.40 billion, compared to the consensus revenue estimate of $4.37 billion.

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

(ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Elanco Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.98%), Shapiro Capital Management LLC (3.21%), Black Creek Investment Management Inc. (3.15%), Wellington Management Group LLP (1.26%), Rokos Capital Management LLP (1.08%) and JPMorgan Chase & Co. (1.07%). Insiders that own company stock include Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover and Rajeev A Modi.
View institutional ownership trends.

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.